Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Michel Pierre Ducreux

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8649-7449; OpenAlex author ID A5085121407. Sources: OpenAlex.

Their work

Papers
43 (first author 3, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
131
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 2 papers · 2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 4 papers · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 4 papers · 2024: 7 papers · 2025: 8 papers · 2026: 6 papers

Papers 43

  1. ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer. First author DOI 10.1016/j.annonc.2026.08.003↗
  2. Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment. Co-author DOI 10.1016/j.ejca.2025.116160↗
  3. Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival. Last author DOI 10.1016/j.ejca.2026.116227↗
  4. Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.116768↗
  5. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  6. Reply to: "FOLFIRINOX for Locally Advanced Pancreatic Cancer: The Need for Individualized Strategies," "Conversion Chemotherapy for Locally Advanced Pancreatic… Co-author DOI 10.1200/jco-25-02162↗
  7. Molecular analysis highlights TREM2 as a discriminating biomarker for patients suffering from pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ctarc.2025.100939↗
  8. Defying the odds: Outstanding survival in lung-only pancreatic cancer treated by Trifluridine-Tipiracil. Co-author DOI 10.1016/j.ejca.2024.115125↗
  9. Pan-RAS inhibitor after KRASG12C treatment in pancreatic cancer? Co-author DOI 10.1016/j.ejca.2025.115588↗
  10. ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer. First author DOI 10.1016/j.esmoop.2025.104528↗
  11. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer. Last author DOI 10.1016/j.esmoop.2025.105826↗
  12. Precision medicine strategy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.esmoop.2025.105899↗
  13. Predictive factors of FOLFIRINOX chemotherapy toxicity in pancreatic adenocarcinoma patients. Co-author DOI 10.1080/14796694.2025.2461442↗
  14. The Role of Computed Tomography-Determined Total Tumor Volume at Baseline in Predicting Outcomes of Patients with Locally Advanced Unresectable or Metastatic P… Co-author DOI 10.3390/cancers18010020↗
  15. Clinical and molecular features of early onset pancreatic adenocarcinoma. Co-author DOI 10.1002/ijc.35135↗
  16. Reply to the Letter to the Editor 'Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten' (in re… Last author DOI 10.1016/j.annonc.2024.05.004↗
  17. Codon-specific KRAS mutations predict survival in advanced pancreatic cancer. Last author DOI 10.1016/j.esmogo.2023.100030↗
  18. Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2024.05.032↗
  19. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  20. Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study. Co-author DOI 10.1186/s12885-024-12016-z↗
  21. Role of molecular biology in the management of pancreatic cancer. Last author DOI 10.4251/wjgo.v16.i7.2902↗
  22. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Last author DOI 10.1016/j.annonc.2023.08.009↗
  23. Adjuvant and neoadjuvant approaches in pancreatic cancer. Last author DOI 10.1097/cco.0000000000000962↗
  24. Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations. Last author DOI 10.3390/biomedicines11092569↗
  25. Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy. Co-author DOI 10.3390/cancers15041235↗
  26. FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope? Co-author DOI 10.1016/j.ejca.2022.09.016↗
  27. Future directions in drug development in pancreatic cancer. Last author DOI 10.1053/j.seminoncol.2021.02.002↗
  28. Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers13184724↗
  29. Systemic treatment of pancreatic cancer revisited. Co-author DOI 10.1053/j.seminoncol.2018.12.003↗
  30. Adjuvant treatment of pancreatic cancer. First author DOI 10.1097/cco.0000000000000546↗
  31. An update on treatment options for pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835919875568↗
  32. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette s… Co-author DOI 10.1186/s12885-019-5889-5↗
  33. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2017.03.022↗
  34. Current standards and new innovative approaches for treatment of pancreatic cancer. Last author DOI 10.1016/j.ejca.2015.12.026↗
  35. A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. Co-author DOI 10.1007/s12029-015-9724-1↗
  36. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Last author DOI 10.1016/j.ctrv.2013.04.004↗
  37. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
  38. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Last author DOI 10.1007/s11912-012-0290-4↗
  39. Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion? Co-author DOI 10.2147/ott.s38520↗
  40. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Co-author DOI 10.1093/annonc/mdr351↗
  41. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Last author DOI 10.1056/nejmoa1011923↗
  42. Pancreatic cancer treatment and research: an international expert panel discussion. Co-author DOI 10.1093/annonc/mdq545↗
  43. Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II tr… Last author DOI 10.1186/1748-717x-6-124↗

Closest collaborators

The 25 strongest of 131 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thierry Conroy · 17 shared papers, 2011–2026 · strength 3.36
  2. Alice Boilève · 14 shared papers, 2023–2026 · strength 2.99
  3. Antoine Hollebecque · 15 shared papers, 2019–2026 · strength 2.82
  4. Cristina Smolenschi · 14 shared papers, 2019–2026 · strength 2.62
  5. Anthony Tarabay · 11 shared papers, 2023–2026 · strength 2.13
  6. Aurélien Lambert · 7 shared papers, 2016–2026 · strength 1.32
  7. David Malka · 7 shared papers, 2014–2024 · strength 0.87
  8. Fanny Jaulin · 3 shared papers, 2024–2025 · strength 0.63
  9. Nathalie Lassau · 3 shared papers, 2025–2026 · strength 0.61
  10. Antoîne Italiano · 3 shared papers, 2024–2026 · strength 0.52
  11. Olivier Bouché · 2 shared papers, 2011–2026 · strength 0.52
  12. Jean‐Luc Van Laethem · 6 shared papers, 2012–2019 · strength 0.42
  13. Kevin Sarti · 1 shared paper, 2025 · strength 0.33
  14. Léa Swales · 1 shared paper, 2025 · strength 0.33
  15. Thomas Theodor Werner Seufferlein · 3 shared papers, 2017–2023 · strength 0.31
  16. Lilian Schwarz · 2 shared papers, 2019–2021 · strength 0.29
  17. Mélanie Debiais · 1 shared paper, 2026 · strength 0.25
  18. Matthieu Delaye · 1 shared paper, 2026 · strength 0.24
  19. Victor Robic · 1 shared paper, 2026 · strength 0.22
  20. Étienne Rouleau · 1 shared paper, 2025 · strength 0.21
  21. Clara Helal · 1 shared paper, 2022 · strength 0.20
  22. Florent Ginhoux · 1 shared paper, 2025 · strength 0.20
  23. Camille Blériot · 1 shared paper, 2025 · strength 0.20
  24. Dimitrios Papakonstantinou · 1 shared paper, 2025 · strength 0.20
  25. Pierre‐Alain Clavien · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.